Torrent Pharmaceuticals Ltd.

NSE: TORNTPHARM | BSE: 500420 | ISIN: INE685A01028 | Industry: Pharmaceuticals
| Expensive Star
3678.2000 -63.70 (-1.70%)
NSE Aug 01, 2025 15:31 PM
Volume: 605.7K
 

3678.20
-1.70%
Motilal Oswal
by India (+10% YoY to INR9b) and Brazil (+7% YoY at INR1.6b) businesses. However, the performance in the US (-3% YoY to INR3.8b) and Germany (-1% YoY to INR2.5b) was weak. 23 October 2019 (GM) expanded 200bp YoY to 73% due to a superior product mix. EBITDA better GM and reduced R&D; expense (6.5% of sales v/s 7.2% in 2QFY19). Accordingly, EBITDA grew 14% YoY to INR5.4b. PBT grew at a higher rate of 44% YoY to INR3b due to lower interest outgo and higher other income. PAT and a lower tax rate. For 1HFY20, sales/EBITDA/PAT grew 7%/14%/35% YoY to INR40b/INR10.8b/INR4.
Number of FII/FPI investors increased from 913 to 923 in Jun 2025 qtr.
More from Torrent Pharmaceuticals Ltd.
Recommended